MX2021000264A - Compuestos peptidicos y usos terapeuticos de los mismos. - Google Patents

Compuestos peptidicos y usos terapeuticos de los mismos.

Info

Publication number
MX2021000264A
MX2021000264A MX2021000264A MX2021000264A MX2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A MX 2021000264 A MX2021000264 A MX 2021000264A
Authority
MX
Mexico
Prior art keywords
therapeutic uses
peptide compounds
dexamethasone
spleen
mouse
Prior art date
Application number
MX2021000264A
Other languages
English (en)
Spanish (es)
Inventor
Eran Ovadia
Avi Ben-Shimon
Original Assignee
Immunity Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69141375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021000264(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunity Pharma Ltd filed Critical Immunity Pharma Ltd
Publication of MX2021000264A publication Critical patent/MX2021000264A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
MX2021000264A 2018-07-11 2019-07-10 Compuestos peptidicos y usos terapeuticos de los mismos. MX2021000264A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL26055518 2018-07-11
PCT/IL2019/050774 WO2020012478A2 (en) 2018-07-11 2019-07-10 Peptide compounds and therapeutic uses of same

Publications (1)

Publication Number Publication Date
MX2021000264A true MX2021000264A (es) 2021-05-12

Family

ID=69141375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021000264A MX2021000264A (es) 2018-07-11 2019-07-10 Compuestos peptidicos y usos terapeuticos de los mismos.

Country Status (21)

Country Link
US (2) US11912790B2 (enExample)
EP (2) EP4566617A3 (enExample)
JP (2) JP7395517B2 (enExample)
KR (1) KR102880543B1 (enExample)
CN (1) CN112351989B (enExample)
AU (2) AU2019300567B2 (enExample)
BR (1) BR112020024748A2 (enExample)
CA (1) CA3100961A1 (enExample)
CO (1) CO2021001290A2 (enExample)
EA (1) EA202190249A1 (enExample)
ES (1) ES3026158T3 (enExample)
HR (1) HRP20250746T1 (enExample)
HU (1) HUE072141T2 (enExample)
IL (2) IL280101B2 (enExample)
MX (1) MX2021000264A (enExample)
PL (1) PL3820882T3 (enExample)
RS (1) RS66946B1 (enExample)
SG (1) SG11202012773QA (enExample)
UA (1) UA130911C2 (enExample)
WO (1) WO2020012478A2 (enExample)
ZA (1) ZA202100587B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
IL272074B2 (en) * 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
JPS4843906B1 (enExample) * 1970-08-11 1973-12-21
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6432407B1 (en) * 1995-12-12 2002-08-13 Takara Shuzo Co., Ltd. Antigenic protein originating in malassezia
WO1997044447A2 (en) * 1996-05-03 1997-11-27 President And Fellows Of Harvard College Transcriptional activation system, activators, and uses therefor
US6861256B2 (en) * 1997-05-15 2005-03-01 The General Hospital Corporation Therapeutic and diagnostic tools for impaired glucose tolerance conditions
GB9711148D0 (en) * 1997-05-31 1997-07-23 Peptide Therapeutics Ltd Human MAFA
EP0928968A1 (en) 1998-01-12 1999-07-14 Universität Basel Screening method for apoptosis and necrosis
US20090087878A9 (en) * 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
CA2443314C (en) 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
US20040204340A1 (en) * 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
AU2005276117C1 (en) 2004-08-23 2013-04-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Peptide inhibitors for mediating stress responses
EP1843779A2 (en) * 2005-02-01 2007-10-17 Attenuon, LLC Compositions containing the anti-angiogenic phscn-peptide
US7704953B2 (en) 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
JP2007228925A (ja) * 2006-03-02 2007-09-13 Kaneka Corp 新規酸化酵素及びそれを用いたグリオキサールの製造方法
JP5351495B2 (ja) * 2008-11-05 2013-11-27 国立大学法人東北大学 スーパーオキシドディスムターゼを用いるアセトアルデヒド分解方法
WO2011033511A1 (en) * 2009-09-17 2011-03-24 Ramot At Tel-Aviv University Ltd. Peptides for the treatment of oxidative stress related disorders
WO2011126882A2 (en) * 2010-03-30 2011-10-13 American Type Culture Collection Therapeutic peptides and their derivatives and therapeutic uses thereof
EP2593595B1 (en) * 2010-07-16 2020-03-11 Avantgen, Inc. Novel peptides and uses thereof
WO2012087964A1 (en) * 2010-12-23 2012-06-28 Codexis, Inc. Gene disruptants producing fatty acyl-coa derivatives
EP3263127B1 (en) 2011-05-23 2019-08-21 Yeda Research and Development Co. Ltd Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
US20140271666A1 (en) * 2013-03-14 2014-09-18 Immune Pharmaceuticals Ltd. Use of anti-eotaxin antibodies for treating inflammatory bowel disease
US20160039877A1 (en) * 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
US8802633B1 (en) 2013-03-18 2014-08-12 Board Of Regents, The University Of Texas System Autophagy-inducing peptide analogs
HUE049261T2 (hu) * 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
US9453061B2 (en) * 2014-08-06 2016-09-27 Brown University Method and compositions for treatment of calcineurin-related diseases
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
WO2017011338A1 (en) 2015-07-10 2017-01-19 President And Fellows Of Harvard College Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use
JP7395517B2 (ja) 2018-07-11 2023-12-11 イミュニティ ファルマ リミテッド ペプチド化合物およびその治療的用途
IL272074B2 (en) 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same

Also Published As

Publication number Publication date
AU2024278477B2 (en) 2026-07-09
WO2020012478A2 (en) 2020-01-16
UA130911C2 (uk) 2026-06-17
IL317252A (en) 2025-01-01
SG11202012773QA (en) 2021-01-28
BR112020024748A2 (pt) 2021-03-23
JP2021531246A (ja) 2021-11-18
HRP20250746T1 (hr) 2025-08-15
CN112351989B (zh) 2024-03-26
EP4566617A2 (en) 2025-06-11
KR102880543B1 (ko) 2025-11-04
JP7395517B2 (ja) 2023-12-11
AU2019300567B2 (en) 2024-09-19
EP4566617A3 (en) 2025-10-01
IL280101B2 (en) 2025-05-01
CN112351989A (zh) 2021-02-09
EA202190249A1 (ru) 2021-05-21
WO2020012478A3 (en) 2020-02-20
HUE072141T2 (hu) 2025-10-28
PL3820882T3 (pl) 2025-08-11
US11912790B2 (en) 2024-02-27
US20210261615A1 (en) 2021-08-26
ES3026158T3 (en) 2025-06-10
US20240190919A1 (en) 2024-06-13
AU2024278477A1 (en) 2025-01-30
IL280101A (en) 2021-03-01
CA3100961A1 (en) 2020-01-16
EP3820882A2 (en) 2021-05-19
CO2021001290A2 (es) 2021-02-26
AU2019300567A1 (en) 2021-02-25
ZA202100587B (en) 2022-07-27
RS66946B1 (sr) 2025-07-31
EP3820882B1 (en) 2025-04-02
IL280101B1 (en) 2025-01-01
JP2024026217A (ja) 2024-02-28
JP7682248B2 (ja) 2025-05-23
KR20210045397A (ko) 2021-04-26
EP3820882C0 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
ZA202200648B (en) Immunoglobulins and uses thereof
EP3946410A4 (en) Therapeutic interferon alpha 1 proteins
GB202200959D0 (en) Polypeptides having anti-senescent effects and uses thereof
NZ765759A (en) Atf5 peptide variants and uses thereof
MX2021008005A (es) Bibliotecas de peptidos y metodos de uso de las mismas.
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
GB2600592B (en) Polypeptide and use thereof
IL290520A (en) Medicinal peptides
SG11202006669RA (en) Peptides and uses thereof
EP3882263A4 (en) GLUCAGON DERIVED PEPTIDE AND USE THEREOF
IL290643A (en) Peptides for transport and methods of using them
IL285144A (en) Medicinal peptides
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
IL292599A (en) tmem219 antibodies and medical uses thereof
WO2020012478A3 (en) Peptide compounds and therapeutic uses of same
WO2018136803A8 (en) Apoc-ii mimetic peptides
EP3947418C0 (en) PEPTIDES AND THEIR USE
AU2020234373A1 (en) Novel peptide and use thereof
EP4066850A3 (en) Peptides and methods of treating dystrophy-related disorders using the same
GB201914682D0 (en) Novel anti-cancer peptides and uses thereof
EP3996737A4 (en) PEPTIDES AND THEIR USES
AU2018275270A1 (en) Peptide PAC1 antagonists
HK40057116A (en) Peptide therapeutics for the treatment of cancer and uses thereof
SG11202101945PA (en) Peptide therapeutics for the treatment of cancer and uses thereof
IL284666A (en) New peptides and their uses